U.S. commercial availability of LEQEMBI IQLIK subcutaneous induction starting by end-August 2026.
SPINRAZA high-dose commercial ramp shifts toward new patient starts and switchbacks in 2027.
Apellis acquisition adds SYFOVRE and Empaveli, with combined growth expected in the mid- to high-teens through at least 2028.
Biogen raised full-year 2026 revenue guidance from a mid-single-digit decline to a mid-single-digit increase.
ZURZUVAE launched in Germany, opening a new international market for the postpartum depression treatment.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Biogen Inc. and 4,900+ companies.